TC BioPharm

69 articles about TC BioPharm

• TCBP Announces Execution of Non-Binding Letter of Intent for Acquisition of NK Platform Technologies

  4/4/2024

  TC BioPharm PLC announced the execution of a non-binding letter of intent as part of its M&A strategy aimed at expanding its therapeutic platform and leveraging NK cells in treating both solid tumors and other indications.

• TCBP Increasing Treatment Capacity with Expanded Manufacturing Process

  4/2/2024

  TC BioPharm PLC a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, announced that it is developing a streamlined and scaled-up manufacturing process which will increase its treatments capacity from 52 patient treatments per year to more than 1,000.

• TCBP Adjourns General Meeting Until a Later Date

  3/19/2024

  TC BioPharm PLC a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, announced that it has adjourned its General Meeting of the Company to a later date.

• TCBP Announces Exercise of Series D Warrants For Cash

  3/18/2024

  TC BioPharm PLC announced that an institutional investor has exercised cash only warrants represented 623,750 American Depository Shares at an exercise price of $2.02.

• TCBP Announces Shareholder Update Call on March 5th 2024

  2/27/2024

  TC BioPharm PLC a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, announced that the company will host a shareholder update call on Tuesday, March 5th, 2024, at 4:30 p.m. ET.

• TCBP Announces MHRA Acceptance of Amendment for ACHIEVE UK Trial

  2/22/2024

  TC BioPharm PLC announced that the MHRA has officially accepted its proposed amendment to the Company's clinical trial authorisation.

• TC BioPharm Management to Participate at Upcoming 7th CAR-TCR Summit Europe

  2/15/2024

  TC BioPharm PLC announced that CEO, Bryan Kobel and Process Development Manager, Dr. Lauren Bor will be featured "Expert Speakers" at the 7th 7th CAR-TCR Summit Europe, February 27-29th in London, UK.

• TCBP Provides Shareholder Update and Highlights Upcoming Milestones

  2/14/2024

  TC BioPharm PLC a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, announced a shareholder update with a projected outlook for the current year.

• TC BioPharm to Present at the Sequire Investor Summit

  1/18/2024

  TC BioPharm today announced its participation at the upcoming Sequire Investor Summit 2024 scheduled for January 23-25, 2024.

• TC BioPharm Regains Compliance with Nasdaq Minimum Bid Price Requirement

  1/4/2024

  TC BioPharm PLC a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announced that on January 2, 2024, the Company received a written notice from The Nasdaq Stock Market.

• TC BioPharm Announces Additional Cost Reduction Steps to Improve Financial Standing and Streamline Efficiencies

  1/3/2024

  TC BioPharm today announced that the Company is undertaking a series of initiatives to reduce costs and drive efficiency in order to reduce cash burn and expand its financial runway.

• TC BioPharm Announces Closing of $3.5 Million Public Offering

  12/22/2023

  TC BioPharm today announced the closing of its previously announced public offering of 1,750,000 of its American Depositary Shares.

• TC BioPharm Announces Pricing of $3.5 Million Public Offering

  12/19/2023

  TC BioPharm today announced the pricing of a public offering of 1,750,000 of its American Depositary Shares.

• TC BioPharm Announces Formation of Commercial Development Division, Led by Industry Veteran, Dr. Lauren Bor Ph.D

  12/18/2023

  TC BioPharm PLC a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announced that the creation of a new Commercial Development Division, which will be headed by Dr. Lauren Bor, PhD.

• TC BioPharm Announces Plan to Implement ADS Ratio Change

  12/13/2023

  TC BioPharm PLC a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announced that it will change its ratio of its American Depositary Shares to ordinary shares from one ADS representing one ordinary share to one ADS representing twenty ordinary shares.

• TC BioPharm Announces FDA Clearance of Phase 1B IND for TCB-008 in Acute Myeloid Leukemia

  11/27/2023

  TC BioPharm announced today that the FDA  provides clearance on the Company's investigational new drug (IND) application for a Phase 1B study in relapse/refractory Acute Myeloid Leukemia (AML).

• TC BioPharm Announces Streamlined Efficiencies and Reduces Overhead with Selection of Single Global CRO for Clinical Trials

  11/2/2023

  TC BioPharm PLC a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announced that it has selected of Fortrea as the Company's Contract Research Organization for global trials, including ACHIEVE and ACHIEVE2.

• TC BioPharm Selects Excellos as CDMO in Anticipation of Expanded US Clinical Trial Requirements

  10/25/2023

  TC BioPharm today announced it has selected Excellos, a San Diego based Contract Development & Manufacturing Organization (CDMO) spun out of San Diego Blood Bank, for its expanding US clinical trial efforts. 

• TC BioPharm Announces Submission of Investigational New Drug (IND) Application to U.S. FDA for Treatment of Relapse/Refractory AML

  10/23/2023

  TC BioPharm therapies today announced submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the use of TCB-008 in the treatment of relapse/refractory Acute Myeloid Leukemia.

• TC BioPharm to Present at the LD Micro Main Event XVI

  9/27/2023

  TC BioPharm today announced that CEO, Bryan Kobel will present at the LD Micro 16th  annual Main Event conference taking place on October 3-5, 2023.